Global microRNA profiles and signaling pathways in the development of cardiac hypertrophy

H J Feng1, W Ouyang1, J H Liu1

  • 1Zhujiang Hospital, Department of Nuclear Medicine, Southern Medical University, Guangzhou, China.

Insights

Cardiac hypertrophy involves complex microRNA (miRNA) dysregulation. This study identifies specific miRNAs and signaling pathways involved, offering potential biomarkers for heart failure prognosis.

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Genetics

Background:

  • Cardiac hypertrophy is a key indicator of heart disease progression and poor prognosis.
  • MicroRNAs (miRNAs) are implicated in cardiac hypertrophy, but their specific roles and interactions with signaling pathways are not fully understood.

Purpose of the Study:

  • To investigate the interaction between hypertrophy-specific signaling pathways and aberrant miRNA expression.
  • To identify potential miRNA biomarkers for cardiac hypertrophy and heart failure prognosis.

Main Methods:

  • Utilized transverse aortic constriction (TAC) in Sprague Dawley rats to induce pathological cardiac hypertrophy.
  • Performed miRNA microarray assays on heart tissues at multiple time points post-surgery.
  • Employed bioinformatics analysis to predict miRNA targets and analyze associated signaling pathways.

Main Results:

  • Identified two distinct sets of differentially expressed miRNAs during cardiac hypertrophy.
  • Bioinformatics analysis revealed that these miRNAs target genes within multiple hypertrophy-specific signaling pathways.
  • Discovered a potential miRNA-mRNA network contributing to cardiac hypertrophy development.

Conclusions:

  • Proposed a novel mechanism for cardiac hypertrophy involving intricate regulation of multiple signaling pathways by miRNAs.
  • Identified specific miRNAs (e.g., rno-miR-331*, rno-miR-3596b, rno-miR-3557-5p, rno-miR-10a, miR-221, miR-190, miR-451) as potential prognostic biomarkers for heart failure.
  • This study provides a foundational understanding of miRNA involvement in cardiovascular hypertrophy.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
54
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K